On Wednesday, Dr. Reddy’s Laboratories Ltd pronounced the unveiling of Lenalidomide Capsules. It is a Therapeutic Equivalent Generic Version of Revlimid (lenalidomide) Capsules sanctioned by the US Food and Drug Administration (USFDA) in the US market.
‘Dr. Reddy’s is qualified for first-to-market, 180 days of Generic drug exceptionally for Lenalidomide Capsules in 2.5 mg and 20 mg strengths’, released the media report from the city-based drug maker explains with this volume-limited takeoff. The drug is a medicine to treat several types of cancers.

“We are extremely pleased to announce the first-to-market launch of two out of six strengths of Lenalidomide Capsules with 180-day market exclusivity. To bring the most affordable generic version to market generates greater patient access for this important drug,” Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s, said.

As formerly stated, the makers of Revlimid’ Celgene’ agreed to provide Dr. Reddy’s with a licence for selling volume-limited amounts of generic lenalidomide capsules in the US, agreeing to a settlement of all outstanding claims of its litigation which gathered sales of about $12.8 billion. The decided-upon percentages remain trustworthy. Being part of the settlement, Dr. Reddy’s is also licensed to sell generic lenalidomide capsules in the US without volume limitation, beginning on January 31, 2026.

Dr. Reddy’s Lenalidomide Capsules are offered in strengths of 2.5 mg, 5 mg, and 10 mg, each piece in a bottle-count size of 28. Furthermore, 15 mg, 20 mg, and 25 mg strengths are available each in a bottle-count size of 21.